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We report a relapsed case of a 25 year-old man with multi- 
drug resistant Salmonella serovar Typhi (MDRST) bacteremia 
who had recently returned from travel in India. Due to unre-
sponsiveness to ciprofloxacin and ceftriaxone, we examined 
the strain’s resistance to quinolones and extended-spectrum β- 
lactamases (ESBLs). The strain had a single gyrA mutation at 
codon 83 (Ser83Phe), which explains its decreased suscep-
tibility to fluoroquinolone and resistance to nalidixic acid. In 
the screening tests of ESBLs, TEM-1 was positive, which is 
beta-lactamase but not ESBL. The patient was finally succes-
sfully treated with meropenem and aztreonam. In the presence 
of clinical unresponsiveness despite favorable sensitivity tests, 
further laboratory evaluations are needed, which should include 
studies of genes related to antibiotic resistance and ESBLs. In 
addition, further prospective trials should be done about the 
possible inclusion of antibiotics not yet mentioned in the 
current guidelines. With MDRST on the rise worldwide, the 
most optimal and effective line of antibiotic defense needs to 
be devised. 
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INTRODUCTION
Typhoid fever, a systemic infectious disease 
caused by Salmonella enterica serovar Typhi, 
affected an estimated 16 million people in the 
1990s worldwide,
1  and the increasing incidence of 
multi-drug-resistant strains poses a risk to public 
health.
2 Investigators from the U.S. Center for 
Disease Control and Prevention estimate that there 
are 21.6 million typhoid cases annually, with the 
yearly incidence varying from 100 to 1,000 cases 
per 100,000 people.
3 An estimated 600,000 deaths 
from enteric fever occur annually throughout the 
world.
1 
Antimicrobial-resistant  Salmonella enterica serovar 
Typhi isolates emerged in the 1970s in Latin 
America
4 and Asia.
5 Meanwhile, Salmonella enterica 
serovar Typhi and Salmonella enterica serovar 
Paratyphi A are the predominant types of Salmonella 
responsible for enteric fever in India. In Korea, no 
resistant strain was documented until 1992, when 
a chloramphenicol, ampicillin, and co-trimoxazole 
resistant strain was isolated from a patient who 
returned from a Southeast Asian country.
6 Lee et 
al. isolated two additional multi-drug-resistant 
strains in 1995,
7 and subsequently, Shin et al. 
reported a chloramphenicol resistance rate of 15% 
among isolates in Korea in 1997.
8 The emergence 
of multi-drug-resistant Salmonella enterica serovar 
Typhi (MDRST) in Korea could be attributed to 
acquisition of resistance by endemic strains from 
other resistant gram-negative bacilli or the spread 
of resistant strains brought back from other 
countries to which there have been recent increases 
in international travel.
7
Here we present a case of a patient who previ-
ously returned from travels in India. He received 
treatment for MDRST bacteremia that was based 
on a bench to bedside approach that included 
studies of genes related to antibiotic resistance 
and extended-spectrum β-lactamases (ESBLs).Hee Jung Yoon, et al. 148
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CASE REPORT
A 25-year-old male patient was admitted to our 
hospital with an ongoing fever that began ten days 
previous. He had just returned from traveling in 
India 20 days before admittance. His past medical 
history was unremarkable and he showed no 
abdominal symptoms or anything else significant 
except for a sore throat. The initial laboratory 
findings showed WBC 6,410/uL, ESR 19 mm/hr, 
CRP 5.31 mg/dL, and AST/ALT 67/87 IU/L. 
Malaria smear showed negative findings. Under 
the initial impression that he might have acute 
pharyngotonsillitis, antibiotic therapy was admi-
nistered with ampicillin 4,000 mg and sulbactam 
2,000 mg per day for four days while he was insti-
tuted. The patient became afebrile and was dis-
charged to the outpatient department for follow 
up. 
Eight days later, the patient returned to the 
emergency room with a fever and abundant watery 
diarrhea. Physical examination upon second 
admission revealed a blood pressure of 110/70 
mmHg, pulse rate 110/min, respiratory rate of 
20/min, and body temperature of 38.5°C. Increased 
bowel sounds and diffuse abdominal tenderness 
were found. The laboratory examination showed 
WBC 3740/uL, ESR 27 mm/hr and CRP 6.15 mg/ 
dL. The AST/ALT were 79/97 IU/L, gamma GTP 
140 IU/L, and LDH 800 IU/L. The Widal agglu-
tination test at the first visit showed values of 
O/A/H 1:20/1:20/1:20, respectively but increased 
to 1:20/20/320 at second visit. The blood culture 
done during the first admission period isolated 
Salmonella serovar Typhi sensitive to antibiotics in-
cluding amikacin, ampicillin, ampicillin/sulbactam, 
aztreonam, cefazolin, cefepime, cefoxitin, ceftriaxone, 
ciprofloxacin, gentamicin, imipenem, piperacillin/ 
tazobactam, and tobramycin except for trimetho-
prim/sulfamethoxazole (TMP-SMX) (MIC≥16/ 
304 μg/mL) in only one pair of blood cultures. 
The sensitivity was assessed by the bioMerieux 
Vitek II susceptibility test system (Hazelwood, 
MO, USA). However, upon the second admission, 
the blood culture showed Salmonella serovar Typhi 
resistant to ampicillin (MIC ≥32 μg/mL), ampicillin- 
sulbactam (MIC ≥ 32/16 μg/mL), and TMP/SMX 
(MIC ≥ 16/304 μg/mL) in three paired blood cul-
tures showing MDR pattern. The MIC results for 
ceftriaxone and ciprofloxacin were ≤ 8 and 1 μg/ 
mL, respectively. Stool and urine cultures were all 
negatives. Abdominal computed tomography 
showed hepatomegaly and splenomegaly. The 
transthoracic echocardiography showed no vege-
tations on the cardiac valves. The patient had a 
relapse from MDRST bacteremia, which we treated 
with ciprofloxacin 400 mg and ceftriaxone 2 g per 
day for 4 days; however, the patient continued in 
poor clinical condition. As a result, we empirically 
changed the antibiotics regimen to meropenem 2 
g and aztreonam 2 g per day and the patient 
showed progressive improvement of clinical and 
laboratorial conditions. We reexamined the isolate 
with the disk diffusion method, which showed 
resistance to nalidixic acid and decreased sensi-
tivity to ciprofloxacin (inhibition diameter of 28
mm). The considerations were done for Salmonella 
serovar Typhi, which has quinolone resistance. 
We assayed the isolated strains for gyrA muta-
tions at codons 81, 83, and 87, using allele-specific 
polymerase chain reaction and restriction frag-
ment length polymorphism (AS-PCR-RFLP) as 
previously described.
2 The single gyrA mutation at 
codon 83 was found, explaining the decreased 
susceptibility to fluoroquinolone and resistance to 
nalidixic acid. Sequencing of the quinolone resis-
tance-determining region (QRDR) of the gyrA 
gene of this isolate revealed a Ser83 Phe substitu-
tion. We also examined whether the isolates ex-
pressed ESBLs. Isolates were subjected to mole-
cular screening for β-lactamases using PCR tests 
as previously described for TEM,
9 SHV,
10 family 
specific CTX-M
11 and plasmid-borne AmpC genes.
12 
The results showed TEM-1 positive finding, which 
is  β-lactamase but not ESBL. After the admini-
stration of meropenem and aztreonam for 14 days, 
follow-up blood and stool cultures were negative 
for Salmonella serovar Typhi and the patient was 
discharged for outpatient department follow up.
DISCUSSION
In India, reports of Salmonella serovar Typhi 
drug resistance began from 1960, with the first 
outbreak of MDRST occurring in Calicut.
13 MDRST 
is defined as strain resistance, which acquired on 
the same plasmid type,
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antibiotics used to treat typhoid fever, namely 
chloramphenicol, ampicillin, and co-trimoxazole. 
A study of the sensitivity pattern of Salmonella in 
northern India found an increase in MDRST from 
53.6% to 63.9% from 1997 to 2001. Out of these 
MDR isolates, 75% were even resistant to amikacin, 
cefotaxime, ciprofloxacin, ceftizoxime, and ceftri-
axone.
14 Initially our patient responded to ampicil-
lin, however, upon switching to oral antibiotics, 
he relapsed and his blood culture upon second 
visit showed MDR pattern that can probably be 
attributed to secondary acquisition of resistance. 
We then treated him with ciprofloxacin and ceftri-
axone, but his clinical state continued to deterio-
rate. The evolution in India of MDR Salmonella 
possessing ESBLs threatens to compromise the 
clinical utility of third-generation cephalosporins.
15 
Most of the MDR S. enterica showed reduced sus-
ceptibility to ampicillin, chloramphenicol, TMP- 
SMX, ofloxacin, and ciprofloxacin, but had good 
susceptibility to extended-spectrum cephalospo-
rins and carbapenems.
16 In addition, Jean et al.
17 
suggested that a carbapenem might be considered 
the drug of choice for the treatment of infections 
caused by cefotaxime- and ciprofloxacin-resistant 
bacteria. Jones et al.
15 also showed complete sus-
ceptibility of endemic Salmonella spp. to meropenem, 
which has potential value as an alternate therapy. 
Imipenem, a carbapenem, was the only antimicro-
bial agent tested with 100% activity against Salmo-
nella spp.,
18 with no association between ciproflo-
xacin and imipenem resistance.
19 As a result, we 
changed the regimen to meropenem and aztreonam. 
Although there have not been any reports on 
intracellular activity of aztreonam against Salmonella 
spp., intracellular activity against E. coli showed a 
dose dependent 32 to 90% decrease of number for 
up to 16 × MBC concentration.
20 Pruul et al. reported 
that exposure of S. typhimurium to aztreonam 
enhances phagocytic killing through modification 
of cell surface structures, which is mediated 
through an increase in surface hydrophobicity 
which enhances bacterial association with leukocyte 
membranes with subsequent phagocytosis and 
intracellular killing.
21 In the mouse typhoid model, 
aztreonam is not only very effective but can com-
pletely eradicate the Salmonella from the reticulo-
endothelial system compared to ampicillin and 
ceftazidime when given early in the infection
22 
and Gotuzzo E et al.
23 reported that aztreonam is 
more effective in the elimination of the infecting 
Salmonella organisms from the bloodstream. Aztre-
onam exhibited superior antimicrobial activity 
compared to other antibiotics, including ceftazidime, 
with inhibition of 90% of the strains by 0.8 micro-
grams/mL (MIC 0.05 to 1.56 micrograms/mL).
24 
Girglis et al. reported that safety and efficacy were 
comparable for ceftriaxone and aztreonam, although 
ceftriaxone was the most cost-effective on an 
inpatient basis due to a more rapid clinical cure.
25 
After changing the regimen, he showed progres-
sive improvement in his condition.
Few cases of treatment failure due to fluoroqui-
nolone resistance in Salmonella strains, including 
Salmonella serovar Typhi, have been reported. 
However, there is evidence of an increasing number 
of strains that are resistant to nalidixic acid and 
exhibit decreased susceptibility to the most recent 
fluoroquinolones used in human therapeutics.
2 
With regard to the mechanisms of quinolone resis-
tance, there are alterations in target enzymes (DNA 
gyrase [gyrA and gyrB] and/or topoisomerase IV 
[parE and parC]) or impaired access to the target 
enzymes, due to changes in porin expression or as 
a result of efflux mechanisms.
26,27 These principal 
means of resistance are a result of chromosomal 
mutations. gyrA gene coding for the A subunit of 
gyrase, whose complex with DNA is the primary 
target of quinolones, has a major role in the 
resistance of quinolone and nalidixic acid.
2 The 
contribution of gyrB mutation to quinolone resis-
tance is still unclear. Topoisomerase IV, whose 
ParC and ParE subunits are homologous to gyrA 
and  gyrB, respectively, is a secondary target. 
Alterations in the ParC and ParE genes at posi-
tions equivalent to those identified in gyrA and 
gyrB participate in strains exhibiting high resis-
tance levels to quinolones.
2 With AS-PCR-RFLP, 
the single gyrA mutation at codon 83 (Ser83Phe) 
was found, explaining its decreased susceptibility 
to fluoroquinolone and resistance to nalidixic acid. 
ESBLs derive mainly from TEM and SHV β- 
lactamases. These enzymes confer resistance to all 
oxyimino cephalosporins and monobactams ex-
cept for cephamycins and carbapenems. ESBL 
gene studies were done in our patient with PCR 
method showing negative results for SHV, CTX- 
M, OXA, DHA and CMY. A positive result for Hee Jung Yoon, et al. 150
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TEM was found, but it was TEM-1 type, which is 
a broad-spectrum β-lactamase but not ESBL. 
TEM-1 is known to confer resistance to ampicillin, 
amoxicillin, and other penicillins as well as to 
early- but not later-generation cephalosporins.
27 It 
is hypothesized that the use of ampicillin-sulbac-
tam at first visit may have acted as a selective 
pressure. The consequent acquisition of TEM-1 by 
Salmonella serovar Typhi may have resulted in 
resistance to ampicillin with the second blood 
culture susceptibility test. 
Careful attention should be taken in the clinical 
field with regard to the lack of an exact correla-
tion between the commonly done in vitro and in 
vivo resistance studies. In the presence of clinical 
unresponsiveness despite favorable sensitivity 
tests, further evaluations like studies of genes 
related to antibiotics resistance and ESBLs should 
be considered. MDRST is on the rise worldwide 
and with increasing levels of international travel, 
even further spread of MDRST can be anticipated. 
In addition, strains resistant to ceftriaxone and 
ciprofloxacin are starting to appear nowadays. So, 
further prospective trials need to be done to 
determine possible use of antibiotics that are not 
yet included in the current treatment guidelines.
3
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